

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ibrutinib for treating chronic lymphocytic leukaemia [ID749]

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Janssen (ibrutinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • African Caribbean Leukaemia Trust • Anthony Nolan • Black Health Agency • Cancer Black Care • Cancer Equality • Cancer52 • Chronic Lymphocytic Leukaemia Support Association • Chronic Myeloid Leukaemia Support Group • Equalities National Council • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Lymphoma AssociationMacmillan Cancer Support • Maggie's Centres • Marie Curie Cancer CareMuslim Council of Britain • Myeloma UK • Muslim Health Network • National Council for Palliative Care • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus • United Kingdom Chronic Lymphocytic Leukaemia Forum 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • Accord Healthcare (fludarabine) • Actavis UK (fludarabine) • Aspen Pharma (chlorambucil) • Baxter Healthcare (cyclophosphamide) • Genzyme (alemtuzumab, fludarabine) • Gilead Sciences (idelalisib) • GlaxoSmithKline (chlorambucil, ofatumumab) • Hospira UK (fludarabine) • Napp Pharmaceuticals (bendamustine) • Pfizer (cyclophosphamide) • Roche Products (rituximab) • Sandoz (cyclophosphamide) • Sanofi (fludarabine) • Teva UK (fludarabine)

National Institute for Health and Care Excellence
Provisional matrix for proposed technology appraisal of ibrutinib for treating relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic leukaemia

Consultees	Commentators (no right to submit or appeal)
<p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Haematology • British Transplantation Society • Cancer Network Pharmacists Forum • Cancer Research UK • National Blood Service • NHS Blood & Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiography • United Kingdom Clinical Pharmacy Association • UK Health Forum • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Clinical Trials Research Unit • Cochrane Haematological Malignancies Group • Institute of Cancer Research • Leuka • Leukaemia Busters • Leukaemia & Lymphoma Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Aberdeen Health Technology Assessment Group • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence
 Provisional matrix for proposed technology appraisal of ibrutinib for treating relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic leukaemia

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.